1. Biosimilars Q&A Regarding Implementation of the Bioligics
2. Quality Considerations in Demonstration Biosimilarity to to a Reference Protein Product
3. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product
¹Ì±¹ ½ÄÇ°ÀǾ౹(FDA)°¡ ¹ÙÀÌ¿À½Ã¹Ð·¯(¹ÙÀÌ¿Àº¹Á¦¾à) °³¹ßÀ» À§ÇÑ °¡À̵å¶óÀÎ ÃʾÈÀ» ÃÖ±Ù ¹ßÇ¥Çß´Ù.
¹Ì±¹Àº ¼¼°è ÃÖ´ëÀÇ ¹ÙÀÌ¿ÀÀǾàÇ° ½ÃÀåÀÌÁö¸¸ ¹ÙÀÌ¿À½Ã¹Ð·¯¿¡ ´ëÇÑ Çã°¡¹æ¾ÈÀÌ ¾ø¾î ¹ÙÀÌ¿À½Ã¹Ð·¯ °³¹ßÀÌ ¾î·Á¿ü´Ù.
FDA°¡ ¹ÙÀÌ¿À½Ã¹Ð·¯ °¡À̵å¶óÀÎÀ» ±¸Ã¼ÈÇÔ¿¡ µû¶ó ¹ÙÀÌ¿À½Ã¹Ð·¯ °³¹ßÀÌ º»°Ý鵃 °ÍÀ̶ó´Â Àü¸Áµµ ³ª¿À°í ÀÖ´Ù.
13ÀÏ °ü·Ã¾÷°è¿¡ µû¸£¸é ¹Ì±¹ FDA´Â Áö³ÁÖ ¹ÙÀÌ¿À½Ã¹Ð·¯ Á¦Ç° °³¹ßÀ» À§ÇÑ °¡À̵å¶óÀÎÀÎ 351(K)ÀÇ ÃʾÈÀ» ¹ßÇ¥Çß´Ù.
Ãʾȿ¡´Â ¹Ì±¹¿¡¼ ¹ÙÀÌ¿À½Ã¹Ð·¯ÀÇ Çã°¡½Åû ½Ã ÇÊ¿äÇÑ ÀýÂ÷ ¹× Á¶°Ç µîÀ» Æ÷ÇÔÇÏ°í ÀÖÀ¸¸ç ÇâÈÄ ÀÇ°ß¼ö·Å±â°£(60ÀÏ)À» °ÅÃÄ 4¿ù Áß ÃÖÁ¾ È®Á¤µÉ ¿¹Á¤ÀÌ´Ù.
Ãʾȿ¡´Â ½ÂÀÎÀ» À§ÇØ Á¦ÃâµÈ ¹ÙÀÌ¿À½Ã¹Ð·¯¿¡ ´ëÇØ ¿À¸®Áö³Î ¹ÙÀÌ¿ÀÀǾàÇ°°úÀÇ
µ¿µî¼ºÀ» Áõ¸íÇϱâ À§ÇÑ °úÇÐÀû Ãø¸é¿¡¼ÀÇ °í·Á»çÇ׿¡ ´ëÇØ ±â¼úµÅ ÀÖ´Ù.
±¸Á¶, ±â´É, ¾à¹°µ¿·ÂÇÐ, ¾à·ÂÇÐ, ÀÓ»óÀû ¾ÈÀü¼º ¹× À¯È¿¼º µî ´Ù¾çÇÑ Ãø¸é¿¡¼ÀÇ ¿À¸®Áö³Î ¹ÙÀÌ¿ÀÀǾàÇ°°úÀÇ ºñ±³¸¦ ºñ·ÔÇØ ¹ßÇö ½Ã½ºÅÛ, Á¦Á¶°øÁ¤, ¹°¸®ÈÇÐÀû Ư¼º µî Ç°Áú Ãø¸éÀÇ µ¿µî¼º È®º¸¸¦ À§ÇØ °í·ÁµÅ¾ß ÇÒ »çÇ×ÀÌ ÁÖ¿ä ³»¿ëÀÌ´Ù.
±Û·Î¹ú ¹ÙÀÌ¿ÀÀǾàÇ°½ÃÀåÀº ¹Ì±¹ÀÌ ÀüüÀÇ 50%, À¯·´ 26%, ÀϺ»ÀÌ 6% µîÀ» Â÷ÁöÇÏ°í ÀÖ´Ù.
À¯·´¿¡¼´Â 2010³â 11¿ù Ç×ü ¹ÙÀÌ¿À½Ã¹Ð·¯¿¡ ´ëÇÑ °¡À̵å¶óÀÎ Á¦Á¤À¸·Î Ç×üÀǾàÇ°ÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ °³¹ßÀÌ °¡´ÉÇØÁ³´Ù.
±×·¯³ª »ó´ëÀûÀ¸·Î ½ÃÀå±Ô¸ð°¡ °¡Àå Å« ¹Ì±¹Àº ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÂÀÎÀ» À§ÇÑ ¹ýÀûÀýÂ÷ ¹Ìºñ·Î ±×µ¿¾È ¹ÙÀÌ¿À½Ã¹Ð·¯ÀÇ °³¹ß ¹× Çã°¡°¡ »ç½Ç »ó ºÒ°¡´ÉÇÑ »óȲÀ̾ú´Ù
|